Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.57 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330038 | 0.88 | XDH (0.74) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL10562056 | 0.88 | ALOX15 (0.79) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL232035 | 0.87 | PKM (0.60) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL2072028 | 0.86 | ALOX15 (0.65) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL5139795 | 0.86 | ALOX15 (0.75) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL10562974 | 0.85 | ALOX15 (1.00) | ALOX15ALOX12PKMPOLBALDH1A1 | |
| SCHEMBL2070701 | 0.83 | ALDH1A1 (0.69) | ALOX15ALOX12PKMPOLBCA12 | |
| SCHEMBL4178094 | 0.82 | ALOX15 (0.74) | ALOX15ALOX12POLBALDH1A1KDM4E | |
| SCHEMBL4194426 | 0.82 | ALOX15 (0.74) | ALOX15ALOX12POLBALDH1A1KDM4E | |
| SCHEMBL18235039 | 0.82 | ALOX15 (0.58) | ALOX15ALOX12PKMPOLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEMICAL LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| EP-4576305-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-06-25 | — | — | EP | disclosed |
| CN-120153509-A | Nonaqueous electrolyte for lithium secondary battery and lithium secondary battery comprising same | 株式会社LG化学 | 2025-06-13 | — | — | CN | disclosed |
| CN-113185486-B | Antitumor agent 3-aryl-4H-chromen-4-one for the treatment of cancer | 肯塔基大学研究基金会 | 2024-05-10 | — | — | CN | disclosed |
| CN-113185486-A | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2021-07-30 | — | — | CN | disclosed |
| CN-107667100-B | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2021-06-08 | — | — | CN | disclosed |
| CN-107667100-A | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2018-02-06 | — | — | CN | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| CN-1129445-A | Isoflavone derivatives | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1996-08-21 | — | — | CN | disclosed |
| EP-0710234-A1 | ISOFLAVONE DERIVATIVES | CHINOIN LTD. (HU) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995003293-A1 | ISOFLAVONE DERIVATIVES | CHINOIN LTD. (HU) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | ALOX15 687/4885ALOX12 1247/4885PKM 3998/4885 |
| US-20260128372-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | CLCN2, CLIC1, RER1 | ALOX15 2044/4885ALOX12 2193/4885PKM 4302/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | ALOX15 1586/4885ALOX12 1633/4885PKM 2178/4885 |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | ALOX15 526/4885ALOX12 508/4885PKM 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.